Nature | Trend Watch

Ebola investment boosts neglected-disease research

Money from industry rises, but public funding falls.

Article tools

Rights & Permissions

TREND WATCH: Funding for work on neglected diseases rose by US$150 million in 2014 to $3.37 billion, but investments made to tackle the Ebola epidemic — which started in West Africa that year — were solely responsible for the increase.

Source: G-FINDER/Policy Cures

The figures come from the annual G-FINDER investment report by Policy Cures, a health-policy analysis firm in Sydney, Australia. As in previous years, HIV/AIDS, malaria and tuberculosis received the most money for research and development.

Around two-thirds of the funding came from the public sector, with philanthropic and industrial money making up the rest. Removing Ebola investments from these figures, however, reveals that public funding for neglected diseases is at a seven-year low, the report says. On the plus side, industry investment rose by 28% to an all-time high. 

Journal name:
Nature
DOI:
doi:10.1038/nature.2015.18975

For the best commenting experience, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will see comments updating in real-time and have the ability to recommend comments to other users.

Comments for this thread are now closed.

Comments

Comments Subscribe to comments

There are currently no comments.

sign up to Nature briefing

What matters in science — and why — free in your inbox every weekday.

Sign up

Listen

new-pod-red

Nature Podcast

Our award-winning show features highlights from the week's edition of Nature, interviews with the people behind the science, and in-depth commentary and analysis from journalists around the world.